167611-99-6

Upstream product

• 1051393-66-8 rac-cis(1S,2R,5R)-3-[(tert-butoxy)carbonyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 33294-81-4 (1R,2S,5S)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 
• 936551-50-7 tert-butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate 

Downstream Products

• 1097133-03-3 (1R,2S,5S)-3-((R)-2-hydroxy-3,3-dimethylbutyryl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097132-97-2 (1R,2S,5S)-3-((R)-2-hydroxy-2-phenylacetyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097133-37-3 (1R,2S,5S)-3-((R)-2-hydroxy-3-phenylpropionyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097133-51-1 (1R,2S,5S)-3-(2-hydroxy-3-methoxy-3-methylbutyryl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097133-43-1 (1R,2S,5S)-3-[(R)-2-hydroxy-3-(1-methylcyclopropyl)propionyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 

Relevant academic research and scientific papers

Synthesis of all four stereoisomers of 3-(tert-butoxycarbonyl)-3- azabicyclo[3.1.0]hexane-2-carboxylic acid

A synthesis of all four stereoisomers of 3-(tert-butoxycarbonyl)-3- azabicyclo[3.1.0]hexane-2-carboxylic acid has been developed, thereby significantly shortening the known literature procedures for the syntheses of these unnatural amino acids. With a simple adjustment of the reaction conditions, we were able to obtain either pure cis or trans acid. Optical resolution was accomplished via diastereomeric salt formation or alternatively via chromatography on a chiral stationary phase. Finally, ab initio calculations gave an explanation for the observed cis selectivity in the initial step.

IMMUNOPROTEASOME INHIBITORS

Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Enantioselective synthesis of cyclopropane α-amino acids: Synthesis of N-Boc-cis-(2S,3R,4S)-3,4-methanoproline and N-Boc-(2S,3R,4S)-3,4-methanoglutamic acid

The title compounds were synthesized by a 5-step facile transformation of the key intermediate 4, itself obtained by a 'one-pot' sulfone-mediated cyclopropanation from chiral synthon (R)-1 and (2R)-glycidyl triflate.